A double-blind, randomized, parallel, comparative study to evaluate the efficacy and safety of an antidiabetic agent repaglinide for the treatment of type 2 diabetes mellitus patients.
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Oct 2006 New trial record.